infectious disease news from FierceBiotech
News
Development chief outlines strategy at Genentech
Genentech's Susan Desmond-Hellmann, president of product development, outlined the biotech giant's development strategy to a group at the Goldman Sachs healthcare conference. In addition to testing Read more...
Symphogen inks $330M collaboration pact with Genentech
Denmark's Symphogen has inked a $330 million collaboration deal with Genentech to discover new antibodies for three infectious disease Read more...
Emergent BioSolutions buys flu vaccine maker
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug Read more...
SPOTLIGHT: Meridian buys recombinant proteins
Meridian Bioscience has agreed to buy a line of infectious disease recombinant proteins from Vybion for an undisclosed sum of money. The pact covers future royalties on product sales. Read more...
Argos garners $35.2M in third round
TVM Capital led a hefty $35.2 million third round of venture capital for Colorado's Argos Therapeutics. The funding will be used to support Argos' Phase II trial of Arcelis immunotherapy drug Read more...
Shareholders stymie VaxGen, Raven merger
VaxGen and Raven Biotechnologies are backing out of their proposed merger after "stronger than anticipated opposition" from shareholders. The companies say that while they initially thought Read more...
Morphotek licenses anti-cancer antibody
Morphotek has inked a deal with Human Monoclonals International to get rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. The company hopes to develop a lead Read more...
FDA cancels meeting as hopes rise for Basilea
The FDA has canceled a scheduled advisory board meeting on Basilea's ceftobiprole antibiotic, a move that Read more...
Zosano rounds up $45M in VC
Fremont, CA-based Zosano Pharma has received $45 million in its second round, bringing its total funding thus far to $90 million. Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and Read more...
Merck's HIV vaccine linked to higher infections rate
Merck researchers have gone deep into the data for its recently shelved HIV vaccine and found evidence that the therapy may have actually made patients more likely to get an infection. Looking at the Read more...
Get more infectious disease coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets